“Robert and David will help shape CHI’s agenda and support our collective mission within the life sciences arena during this challenging time." - CHI President & CEO David L. Gollaher, Ph.D.
LA JOLLA (PRWEB) November 25, 2013
California Healthcare Institute (CHI) announced today the election of two senior executives to serve on its board of directors: Robert Perez, MBA, President and Chief Operating Officer of Cubist Pharmaceuticals, and David Stover, Ph.D., Senior Vice President and Site Head of Agensys (a wholly owned subsidiary of Astellas). CHI is a nonprofit, public policy research organization, representing leading California academic institutions, biotechnology, medical device, diagnostics and pharmaceutical firms.
“We are pleased to welcome executives from Cubist Pharmaceuticals and Agensys to our board of directors,” said CHI President and CEO David L. Gollaher, Ph.D. “Robert and David will help shape CHI’s agenda and support our collective mission within the life sciences arena during this challenging time. Their extensive experience as executives in the biomedical industry will bolster our efforts to represent the interests of our members in Sacramento and Washington.”
Perez has served as Cubist’s President and Chief Operating Officer since July 2012. Perez joined Cubist in 2003 as Senior Vice President of Sales and Marketing and went on to lead the company’s commercial operations prior to assuming his current role as President and COO. Prior to joining Cubist, he served as Vice President of Biogen, Inc.'s CNS Business Unit where he was responsible for leading the U.S. neurology franchise. From 1995 to 2001 he served as their Regional Director, Director of Sales, and as Commercial Executive for Avonex®, Biogen’s treatment for multiple sclerosis. From 1987 to 1995, Perez held various sales and marketing positions at Zeneca Pharmaceuticals, ultimately serving as Regional Business Director, responsible for sales, marketing and national accounts for the Western Regional Business Unit. Perez is a member of the Board of Advisors of the Citizen School of Massachusetts. He is a director of BSCP, AMAG Pharmaceuticals, Inc., the Biomedical Enterprise Program, a graduate degree program that is jointly administered by the Harvard-MIT Division of Health Sciences and Technology, the MIT Sloan School of Management, and the Dana-Farber Cancer Institute, Inc. Perez received a B.S. from California State University, Los Angeles and his MBA from UCLA Anderson School of Management.
Stover is currently Senior Vice President and Site Head of Agensys (a wholly owned subsidiary of Astellas) responsible for research, manufacturing, and development of biotherapeutics for the treatment of cancer. He has more than 20 years of experience in both small molecule and antibody drug discovery, predominantly in the field of oncology. Prior to joining Agensys in 2009, Stover was the Director of Oncology Biotherapeutics at Novartis from 2003 - 2009. Before joining Novartis, he served as the Vice President of Drug Discovery at MDS Proteomics from 2000 – 2003. From 1997 – 2000, Stover was the Director of Biochemistry at Kinetix Pharmaceuticals, Inc. Prior to serving at Kinetix Pharmaceuticals, Stover was a scientist and oncology project leader at Ciba-Geigy/Novartis from 1993 – 1997. Stover earned his doctorate in biochemistry from the University of Washington and his bachelor’s degree in zoology from Duke University.
About California Healthcare Institute
CHI represents more than 275 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s website is http://www.chi.org. Follow us on Twitter @calhealthcare, Facebook, LinkedIn and YouTube.